The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review - PubMed
Review
. 2023 Mar;79(3):371-381.
doi: 10.1007/s00228-023-03454-y. Epub 2023 Jan 26.
Affiliations
- PMID: 36700997
- DOI: 10.1007/s00228-023-03454-y
Review
The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review
Ehsan Motaghi et al. Eur J Clin Pharmacol. 2023 Mar.
Abstract
Purpose: Previous studies have shown that tetrahydrocannabinol (THC), the main psychoactive component of cannabis, can impair cognitive abilities. There is also some evidence that cannabidiol (CBD), the most abundant non-intoxicating constituent of cannabis, can attenuate these effects. The purpose of this study was to investigate the effects of THC:CBD oromucosal spray (with equal parts THC and CBD) on cognition compared with control conditions in human studies.
Methods: A systematic literature search was performed on four major bibliographic databases. Studies were included in the present review if they evaluated the cognitive effects of THC:CBD oromucosal spray compared with a control condition.
Results: Ten studies were identified (7 on patients with multiple sclerosis, 1 on those with Huntington, and 2 on healthy volunteers) with 510 participants in total. There was considerable heterogeneity among the studies in terms of dose and duration of administration. All studies have used an equal or nearly equal dose of THC and CBD.
Conclusions: Although the results across studies were somewhat inconsistent, most evidence revealed that there is no significant difference between THC:CBD oromucosal spray and control treatments in terms of cognitive outcomes. However, more trials are needed with longer follow-up periods, and dose considerations, particularly comparing lower and higher doses of the spray.
Keywords: Cannabidiol; Cannabinoid; Multiple sclerosis; Nabiximols; Sativex.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Celius EG, Vila C. Celius EG, et al. Brain Behav. 2018 Apr 6;8(5):e00962. doi: 10.1002/brb3.962. eCollection 2018 May. Brain Behav. 2018. PMID: 29761015 Free PMC article. Review.
-
Lee D, Karschner EL, Milman G, Barnes AJ, Goodwin RS, Huestis MA. Lee D, et al. Drug Alcohol Depend. 2013 Jun 1;130(1-3):68-76. doi: 10.1016/j.drugalcdep.2012.10.011. Epub 2012 Nov 10. Drug Alcohol Depend. 2013. PMID: 23146820 Free PMC article. Clinical Trial.
-
Vermersch P, Trojano M. Vermersch P, et al. Eur Neurol. 2016;76(5-6):216-226. doi: 10.1159/000449413. Epub 2016 Oct 13. Eur Neurol. 2016. PMID: 27732980
Cited by
-
Arkell TR, Manning B, Downey LA, Hayley AC. Arkell TR, et al. CNS Drugs. 2023 Nov;37(11):981-992. doi: 10.1007/s40263-023-01046-z. Epub 2023 Nov 9. CNS Drugs. 2023. PMID: 37945917 Free PMC article. Clinical Trial.
References
-
- Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat 73(3):292–297 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical